ReviewFrontiers in cellular and infection microbiology2012
Novel approaches to develop Rift Valley fever vaccines.
Review in Frontiers in cellular and infection microbiology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 47 citations in OpenAlex.
- Article
- RT-qPCR genotyping assays for differentiating Rift Valley fever phlebovirus strains.Journal of virological methods · 2023Article
- Article
- Emerging viruses and current strategies for vaccine intervention.Clinical and experimental immunology · 2019Review
- Review
- Transcriptome profiling in Rift Valley fever virus infected cells reveals modified transcriptional and alternative splicing programs.PloS one · 2019Article
- Article
- Attenuation and protective efficacy of Rift Valley fever phlebovirus rMP12-GM50 strain.Vaccine · 2017Article
- Recent advances in the development of antiviral therapeutics for Rift Valley fever virus infection.Future virology · 2017Review
- Current Status of Rift Valley Fever Vaccine Development.Vaccines · 2017Review
- Rift Valley fever vaccines: an overview of the safety and efficacy of the live-attenuated MP-12 vaccine candidate.Expert review of vaccines · 2017Review
- Distinct virulence of Rift Valley fever phlebovirus strains from different genetic lineages in a mouse model.PloS one · 2017Article
- The two faces of Rift Valley fever virus virulence factor NSs: The development of a vaccine and the elucidation of pathogenesis.Virulence · 2016Article
- The role of signal transducer and activator of transcription 3 in Rift Valley fever virus infection.Virology · 2016Article
- Experimental Infection of Calves by Two Genetically-Distinct Strains of Rift Valley Fever Virus.Viruses · 2016Article
- Self-disseminating vaccines for emerging infectious diseases.Expert review of vaccines · 2016Review
- Countermeasure development for Rift Valley fever: deletion, modification or targeting of major virulence factorFuture virology · 2014Article
- Immunogenicity and efficacy of a chimpanzee adenovirus-vectored Rift Valley fever vaccine in mice.Virology journal · 2013Article
- Review
- Vaccines for viral hemorrhagic fevers--progress and shortcomings.Current opinion in virology · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Rift Valley fever (RVF) is endemic to sub-Saharan Africa, and has spread into Madagascar, Egypt, Saudi Arabia, and Yemen. Rift Valley fever virus (RVFV) of the family Bunyaviridae, genus Phlebovirus causes hemorrhagic fever, neurological disorders or blindness in humans, and high rate abortion and fetal malformation in ruminants. RVFV is classified as a Category A Priority pathogen and overlap select agent by CDC/USDA due to its potential impact on public health and agriculture. There is a gap in the safety and immunogenicity in traditional RVF vaccines; the formalin-inactivated RVFV vaccine TSI-GSD-200 requires three doses for protection, and the live-attenuated Smithburn vaccine has a risk to cause abortion and fetal malformation in pregnant ruminants. In this review, problems of traditional vaccines and the safety and efficacy of recently reported novel RVF candidate vaccines including subunit vaccines, virus vector, and replicons are discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.